PURPOSE: Of the numerous complications associated with cancer and cancer treatment, peripheral neuropathy is a deleterious and persistent patient complaint commonly attributed to chemotherapy. The present study investigated the occurrence of subclinical peripheral neuropathy in patients with colorectal cancer before the initiation of chemotherapy. EXPERIMENTAL DESIGN: Fifty-two patients underwent extensive quantitative sensory testing (QST) before receiving chemotherapy. Changes in multiple functions of primary afferent fibers were assessed and compared with a group of healthy control subjects. Skin temperature, sensorimotor function, sharpness detection, and thermal detection were measured, as was touch detection, using both conventional (von Frey monofilaments) and novel (Bumps detection test) methodology. RESULTS: Patients had subclinical deficits, especially in sensorimotor function, detection of thermal stimuli, and touch detection that were present before the initiation of chemotherapy. The measured impairment in touch sensation was especially pronounced when using the Bumps detection test. CONCLUSIONS: The patients with colorectal cancer in this study exhibited deficits in sensory function before undergoing chemotherapy treatment, implicating the disease itself as a contributing factor in chemotherapy-induced peripheral neuropathy. The widespread nature of the observed deficits further indicated that cancer is affecting multiple primary afferent subtypes. Specific to the finding of impaired touch sensation, results from this study highlight the use of newly used methodology, the Bumps detection test, as a sensitive and useful tool in the early detection of peripheral neuropathy.
PURPOSE: Of the numerous complications associated with cancer and cancer treatment, peripheral neuropathy is a deleterious and persistent patient complaint commonly attributed to chemotherapy. The present study investigated the occurrence of subclinical peripheral neuropathy in patients with colorectal cancer before the initiation of chemotherapy. EXPERIMENTAL DESIGN: Fifty-two patients underwent extensive quantitative sensory testing (QST) before receiving chemotherapy. Changes in multiple functions of primary afferent fibers were assessed and compared with a group of healthy control subjects. Skin temperature, sensorimotor function, sharpness detection, and thermal detection were measured, as was touch detection, using both conventional (von Frey monofilaments) and novel (Bumps detection test) methodology. RESULTS:Patients had subclinical deficits, especially in sensorimotor function, detection of thermal stimuli, and touch detection that were present before the initiation of chemotherapy. The measured impairment in touch sensation was especially pronounced when using the Bumps detection test. CONCLUSIONS: The patients with colorectal cancer in this study exhibited deficits in sensory function before undergoing chemotherapy treatment, implicating the disease itself as a contributing factor in chemotherapy-induced peripheral neuropathy. The widespread nature of the observed deficits further indicated that cancer is affecting multiple primary afferent subtypes. Specific to the finding of impaired touch sensation, results from this study highlight the use of newly used methodology, the Bumps detection test, as a sensitive and useful tool in the early detection of peripheral neuropathy.
Authors: Lajos Pusztai; Tito R Mendoza; James M Reuben; Monica M Martinez; Jie S Willey; Juanita Lara; Abdul Syed; Herbert A Fritsche; Eduardo Bruera; Daniel Booser; Vicente Valero; Banu Arun; Nuhad Ibrahim; Edgardo Rivera; Melanie Royce; Charles S Cleeland; Gabriel N Hortobagyi Journal: Cytokine Date: 2004-02-07 Impact factor: 3.861
Authors: Alyssa K Kosturakis; Zijing He; Yan Li; Jessica A Boyette-Davis; Nina Shah; Sheeba K Thomas; Haijun Zhang; Elisabeth G Vichaya; Xin Shelley Wang; Gwen Wendelschafer-Crabb; William R Kennedy; Donald A Simone; Charles S Cleeland; Patrick M Dougherty Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty Journal: Brain Behav Immun Date: 2015-06-09 Impact factor: 7.217
Authors: Stephen N Housley; Paul Nardelli; Dario I Carrasco; Travis M Rotterman; Emily Pfahl; Lilya V Matyunina; John F McDonald; Timothy C Cope Journal: Cancer Res Date: 2020-04-28 Impact factor: 12.701
Authors: Melisa L Wong; Bruce A Cooper; Steven M Paul; Gary Abrams; Kimberly Topp; Kord M Kober; Margaret A Chesney; Melissa Mazor; Mark A Schumacher; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2019-02-15 Impact factor: 3.603
Authors: Mariana de Carvalho Barbosa; Alyssa K Kosturakis; Cathy Eng; Gwen Wendelschafer-Crabb; William R Kennedy; Donald A Simone; Xin S Wang; Charles S Cleeland; Patrick M Dougherty Journal: Cancer Res Date: 2014-09-02 Impact factor: 12.701
Authors: Elisabeth G Vichaya; Xin Shelley Wang; Jessica A Boyette-Davis; Tito R Mendoza; Zijing He; Sheeba K Thomas; Nina Shah; Loretta A Williams; Charles S Cleeland; Patrick M Dougherty Journal: Cancer Chemother Pharmacol Date: 2013-03-31 Impact factor: 3.333
Authors: Jennifer S Gewandter; Joanna Brell; Guido Cavaletti; Patrick M Dougherty; Scott Evans; Lynn Howie; Michael P McDermott; Ann O'Mara; A Gordon Smith; Daniela Dastros-Pitei; Lynn R Gauthier; Simon Haroutounian; Matthew Jarpe; Nathaniel P Katz; Charles Loprinzi; Paul Richardson; Ellen M Lavoie-Smith; Patrick Y Wen; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2018-07-27 Impact factor: 9.910
Authors: Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José M Castro-Lopes; Nuno Lunet Journal: Support Care Cancer Date: 2015-09-18 Impact factor: 3.603